Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-GemOD followed by ASCT for advanced-stage extranodal NK/T-cell lymphoma
ChiCTR1800015640Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegaspargase, gemcitabine, oxaliplatin and dexamethasone in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: overall survival. Started Mar 2018; status: recruiting.
02
Drugs
pegaspargasegemcitabineoxaliplatindexamethasone
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR1800015640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015640.